Loading stock data…
Purple Biotech Ltd. (PPBT)
$1.74+0.06 (+3.57%)
After Hours$1.68-0.06 (-3.28%)· Last close Jun 29
Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Purple Biotech Ltd in the Healthcare sector is trading at $1.74 with a market capitalization of $3M. Wall Street consensus targets $30.00 (1 analysts), implying a +1624.1% move over the next 12 months. The stock is currently near its 52-week low of $1.42, remaining 67.8% below its 200-day moving average. On fundamentals, Piotroski 1/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 22 is oversold, raising the odds of a near-term bounce. The Whystock Score of 35/100 signals elevated caution as multiple indicators diverge.
Ecosystem Influences
Sell-side targets imply +1624.1% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 22) — potential for technical mean-reversion
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$2.25M↑ | -$2.96M↓ | -$1.37M↓ | -$1.24M↑ | -$1.41M |
| Net Income | -$86,000↑ | -$23.55M↓ | -$1.30M↓ | -$1.08M↓ | -$453,000 |
Peer Comparison
JNJUNHPFE
Fundamentals
Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that bl...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.75M
P/E Ratio
Value territory. Trading at a high yield relative to earnings.
0.00
Beta
Defensive asset. Lower volatility than the S&P 500.
-0.57
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-267.63%
Volume
Today's trading volume
58,788
